tstbio iprotin Atherosclerotic Cardiovascular Disease Reader CE FDA IVD

Email us for pricing at info@poc-diagnostics.co.uk

For Chronic Disease

Lp(a) and ApoB are advanced risk biomarkers, independently linked to atherosclerotic cardiovascular disease (ASCVD). They play a crucial role in the early detection, diagnosis, and monitoring of cardiovascular health. 

For Patients

No more traditional venous blood draws. With just a single fingertip blood sample, testing becomes quick, easy, and minimally invasive—reducing discomfort while enabling more accessible and routine monitoring.

Lab-Quality Results, Anytime, Anywhere

Perfect for screening, rapid decision-making, 
and point-of-care testing.

The iProtin System brings laboratory precision to the 
point of care:

• Just one drop of finger-prick blood (5 μL)
• No centrifugation or extra preparation required
  
• Quick and effortless operation
  
• Compact, portable iProtin Reader
  
• Get reliable results in only 3 minutes

Test Range

CRP Range  0.2 - 10 mg/dL
Normal   Range:  < 1mg/dL
Abnormal   Range:  >1mg/dL

Lp(a) Range  10 - 140 mg/dL 
Normal   Range:   <  30 mg/dL

ApoB Range  10 - 200 mg/dL 
Normal   Range  for   Males:  46  -  174   mg/dL
Normal   Range  for   Females:  46  -  142 mg/dL

*Shelf life at room temperature: 1 Year

CRP, Lp(a), ApoB Specification

	CRP	Lp(a)	ApoB
Intended Use	Evaluation and tracking of inflammation	Risk evaluation of CVD (genetic)	Risk evaluation of CVD (metabolic)
Sample Type	Whole blood mixed with enhance	Whole blood	Diluted whole blood
Sample Type Sample Volume	5 μL	5 μL	5 μL
Measuring Time	3 mins	40 sec	40 sec
Sensitivity	LoQ= 0.1 mg/dL	LoD= 5.83 mg/dL	LoD= 8.01 mg/dL

Cardiovascular Risk Indicators

Assess heart health with advanced biomarkers:

• ApoB: Stronger predictor of LDL particle levels,
providing reliable insights even in patients with high
triglycerides

• hsCRP: Measures systemic inflammation to support
ASCVD risk assessment

• Lp(a): Genetic risk factor that may require medical
intervention

With the iProtin System – Evaluate ASCVD risk 
quickly and conveniently at the point of care, giving 
physicians real-time insights for diagnosis, 
monitoring, and digital health management.

Risk-Based ApoB Goal Levels

• Very high-risk population: <65 mg/dL
• High-risk population: <80 mg/dL
• Moderate-risk patients: <100 mg/dL

European Heart Journal, Volume 41, Issue 1, 1 January 2020, Pages 111–188.

Assessment of Cardiovascular Risk: 
Lp(a) and CRP/hsCRP

Lp(a) level >50 mg/dL (>125 nmol/L): Considered as a 
CV risk-enhancing factor.

European Heart Journal, ehaf190, 29 August 2025.

CRP/hsCRP levels:

• <0.1 mg/dL: Desirable range, associated with an extremely low risk of cardiovascular diseases.

• 0.1-0.3 mg/dL: Moderate CVD risk range. Recommend regular follow-up.

• 0.3-1 mg/dL: High CVD risk range, potentially linked to bacterial infection. Recommend regular follow-up. 

• >1 mg/dL: Acute inflammation. Immediate medical attention is needed.

Circulation, Volume 108, Issue 12, 23 September 2003; Pages e81-e85.